The AML1/MTG8 Fusion Transcript in t(8;21) Positive AML and its Implication for the Detection of Minimal Residual Disease

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Hematology

• Publication date

  2000-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1080/10245332.2000.11746532PMID 27420928
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Real-Time Quantitative PCR

  2002cited by this paper
• Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients.

  2000cited by this paper
• A quantitative reverse transcriptase polymerase chain reaction method for the detection of leukaemic cells with t(8;21) in peripheral blood

  2000cited by this paper
• Biological Characteristics of the Leukemia-Associated Transcriptional Factor AML1 Disclosed by Hematopoietic Rescue ofAML1-Deficient Embryonic Stem Cells by Using a Knock-in Strategy

  2000cited by this paper
• Quantitation of minimal residual disease in t(8;21)‐positive acute myelogenous leukemia patients using real‐time quantitative RT‐PCR

  2000cited by this paper
• Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse.

  2000cited by this paper
• Comparison of nested competitive RT-PCR and real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21) positive acute myelogenous leukemia

  2000cited by this paper
• Detection of minimal residual disease in acute myeloid leukaemia: methodologies, clinical and biological significance

  1999cited by this paper
• THE AML1‐ETO CHIMAERIC TRANSCRIPTION FACTOR IN ACUTE MYELOID LEUKAEMIA: BIOLOGY AND CLINICAL SIGNIFICANCE

  1999cited by this paper
• Block of granulocytic differentiation of 32Dcl3 cells by AML1/ETO(MTG8) but not by highly expressed Bcl-2

  1999cited by this paper
• Real‐time RT‐PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)‐positive AML patients

  1999cited by this paper
• Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: biology and clinical implications

  1999cited by this paper
• Association between structural and numerical chromosomal aberrations in acute myeloblastic leukemia: a study by RT-PCR and FISH in 447 patients with de-novo AML

  1999cited by this paper
• Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real‐time RT‐PCR exemplified by t(12;21) TEL‐AML1 fusion transcript

  1999cited by this paper
• Comparison of karyotype analysis and RT-PCR for AML1/ETO in 204 unselected patients with AML

  1998cited by this paper
• The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation.

  1998cited by this paper
• Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes

  1998cited by this paper
• Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real‐time quantitative RT‐PCR

  1998cited by this paper
• Detection of karyotypic aberrations in acute myeloblastic leukaemia: a prospective comparison between PCR/FISH and standard cytogenetics in 140 patients with de novo AML

  1998cited by this paper
• Improved quantitation of minimal residual disease in multiple myeloma using real-time polymerase chain reaction and plasmid-DNA complementarity determining region III standards.

  1998cited by this paper
• The MYND Motif Is Required for Repression of Basal Transcription from the Multidrug Resistance 1 Promoter by the t(8;21) Fusion Protein

  1998cited by this paper
• ETO, a Target of t(8;21) in Acute Leukemia, Interacts with the N-CoR and mSin3 Corepressors

  1998cited by this paper
• The t(8;21) Fusion Product, AML-1–ETO, Associates with C/EBP-α, Inhibits C/EBP-α-Dependent Transcription, and Blocks Granulocytic Differentiation

  1998cited by this paper
• Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay

  1998cited by this paper
• The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

  1998cited by this paper
• Development of an interphase fluorescent in situ hybridization (FISH) test to detect t(8;21) in AML patients

  1998cited by this paper
• Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

  1998cited by this paper
• Aberrant Recruitment of the Nuclear Receptor Corepressor-Histone Deacetylase Complex by the Acute Myeloid Leukemia Fusion Partner ETO

  1998cited by this paper
• Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors.

  1998cited by this paper
• ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex.

  1998cited by this paper
• AML1(−/−) embryos do not express certain hematopoiesis-related gene transcripts including those of the PU.1 gene

  1998cited by this paper
• Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials

  1997cited by this paper
• AML1A and AML1B can transactivate the human IL-3 promoter.

  1997cited by this paper
• Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene

  1997cited by this paper
• Rapid disappearance of AML1/ETO fusion transcripts in patients with t(8;21) acute myeloid leukemia following bone marrow transplantation and chemotherapy.

  1997cited by this paper
• Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461.

  1997cited by this paper
• Expression of AML1/MTG8 transcripts in clonogenic cells grown from bone marrow of patients in remission of acute myeloid leukaemia with t(8;21)

  1997cited by this paper
• Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22).

  1997cited by this paper
• AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.

  1996cited by this paper
• The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo.

  1996cited by this paper
• Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor.

  1996cited by this paper
• Regulation of GM-CSF gene transcription by core-binding factor.

  1996cited by this paper
• Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia.

  1996cited by this paper
• Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia.

  1996cited by this paper
• Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11.

  1996cited by this paper
• CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter

  1996cited by this paper
• Leukemia-associated changes identified by quantitative flow cytometry. IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21).

  1996cited by this paper
• The AML1/ETO fusion protein activates transcription of BCL-2.

  1996cited by this paper
• DNA-binding domain of AML1, expressed in t(8;21) and t(3;21) myeloid leukemias, inhibits PEBP2/CBF DNA-binding but is not sufficient to transform 32D cl3 myeloid cells.

  1996cited by this paper
• Real time quantitative PCR.

  1996cited by this paper
• SERIAL QUANTIFICATION OF MINIMAL RESIDUAL DISEASE OF t(8;21) ACUTE MYELOGENOUS LEUKAEMIA WITH RT‐COMPETITIVE PCR ASSAY

  1996cited by this paper
• Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis.

  1996cited by this paper
• Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8; 21).

  1996cited by this paper
• ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease.

  1996cited by this paper
• A novel method for real time quantitative RT-PCR.

  1996cited by this paper
• Molecular detection of t(8;21)/AML1‐ETO in AML M1/M2: correlation with cytogenetics, morphology and immunophenotype

  1996cited by this paper
• The CBFb subunit is essential for CBFa2 (AML1)function in vivo

  1996cited by this paper
• Quantitative analysis of AML1/ET0 transcripts in peripheral blood stem cell harvests from patients with t(8;21) acute myelogenous leukaemia

  1995cited by this paper
• The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B.

  1995cited by this paper
• Use of the polymerase chain reaction in the detection of A ML1/ETO fusion transcript in t(8;21)

  1995cited by this paper
• Disappearance of AML1 ‐MTG8(ETO) fusion transcript in acute myeloid leukaemia patients with t(8;21) in long‐term remission

  1995cited by this paper
• The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation

  1995cited by this paper
• Expression of AML1 and ETO Transcripts in hematopoietic cells.

  1995cited by this paper
• Quantitative PCR techniques and applications.

  1995cited by this paper
• AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia.

  1995cited by this paper
• Identical fusion transcript associated with different breakpoints in the AML1 gene in simple and variant t(8;21) acute myeloid leukemia.

  1995cited by this paper
• An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms.

  1995cited by this paper
• PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2 beta/CBF beta proto-oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells

  1994cited by this paper
• Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction.

  1994cited by this paper
• The ETO portion of acute myeloid leukemia t(8;21) fusion transcript encodes a highly evolutionarily conserved, putative transcription factor.

  1994cited by this paper
• Detection of t(8;21) by reverse transcriptase polymerase chain reaction in patients in remission of acute myeloid leukaemia type M2 after chemotherapy or bone marrow transplantation.

  1994cited by this paper
• Correlation between cell morphology and expression of the AML1/ETO chimeric transcript in patients with acute myeloid leukemia without the t(8;21).

  1994cited by this paper
• AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation.

  1994cited by this paper
• An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation.

  1993cited by this paper
• Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission.

  1993cited by this paper
• Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation.

  1993cited by this paper
• Translocation breakpoints are clustered on both chromosome 8 and chromosome 21 in the t(8;21) of acute myeloid leukemia.

  1993cited by this paper
• Quantitation of follicular non‐Hodgkin's lymphoma cells carrying t(14;18) by competitive polymerase chain reaction

  1993cited by this paper
• Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction.

  1993cited by this paper
• Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions

  1993cited by this paper
• The t(8;21) translocation in acute myeloid leukemia results in production of an AML1‐MTG8 fusion transcript.

  1993cited by this paper
• Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt.

  1992cited by this paper
• Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children.

  1992cited by this paper
• Consistent disruption of the AML1 gene occurs within a single intron in the t(8;21) chromosomal translocation.

  1992cited by this paper
• Competitive PCR

  1992cited by this paper
• Recurring chromosome abnormalities in leukemia and lymphoma.

  1990cited by this paper
• The Fourth International Workshop on Chromosomes in Leukemia: a prospective study of acute nonlymphocytic leukemia. Chicago, Illinois, U.S.A., September 2-7, 1982.

  1984cited by this paper
• Zwischenmolekulare Energiewanderung und Fluoreszenz

  1948cited by this paper

• 19 Overview of Real-Time PCR Principles

  2017cites this paper
• Overview of Real-Time PCR Principles

  2012cites this paper
• Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease

  2011cites this paper
• Point-of-care systems for rapid DNA quantification in oncology.

  2008cites this paper
• ARRAY COMPARATIVE GENOMIC HYBRIDIZATION IN SARCOMAS

  2007cites this paper
• Klinische Bedeutung des Nachweises minimaler Residualerkrankung bei Leukämien, Lymphomen und soliden Tumoren

  2006cites this paper
• The power of real-time PCR.

  2005cites this paper
• Clinical significance of minimal residual disease in childhood acute myeloid leukemia

  2004cites this paper
• Detection of Minimal Residual Disease in Acute Myelogenous Leukemia

  2004cites this paper
• Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement

  2003cites this paper
• Monitoring minimal residual disease in AML: the right time for real time

  2003cites this paper
• Quantitative real-time PCR in cancer research.

  2003cites this paper
• Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.

  2003cites this paper
• Quantitative real-time PCR: a powerful ally in cancer research.

  2003cites this paper
• Factors Influencing Real-Time RT-PCR Results: Application of Real-Time RT-PCR for the Detection of Leukemia Translocations

  2002cites this paper
• Real-time PCR for monitoring minimal residual disease and chimerism in patients after allogeneic transplantation

  2002cites this paper
• Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream.

  2002cites this paper